XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 30, 2013
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   $ 36,161 $ 60,827  
Deferred Revenue   16,495   $ 12,739
Drug product revenue recognized   36,161 60,827  
Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   24,161 18,881  
Drug product revenue recognized   24,161 18,881  
Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   2,109 7,594  
Drug product revenue recognized   $ 2,109 7,594  
AstraZeneca Agreements [Member] | U.S./RoW [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Upfront, non-contingent, non-refundable and time-based payments $ 1,200,000      
Additional consideration based on net sales description   low 20% range    
Aggregate consideration received excluding drug product revenue   $ 439,000    
AstraZeneca Agreements [Member] | China [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Upfront, non-contingent, non-refundable and time-based payments $ 376,700      
Aggregate considerations received   77,200    
Direct Sales [Member] | Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   2,789 2,658  
Drug product revenue recognized   $ 2,789 $ 2,658